Critical Survey: Capricor Therapeutics (NASDAQ:CAPR) versus Glucose Health (OTCMKTS:GLUC)

Capricor Therapeutics (NASDAQ:CAPR) and Glucose Health (OTCMKTS:GLUC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Valuation and Earnings

This table compares Capricor Therapeutics and Glucose Health”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	$22.27 million	59.45	-$40.47 million	($1.80)	-16.09
Glucose Health	$380,000.00	11.57	-$320,000.00	($0.03)	-7.17

Glucose Health has lower revenue, but higher earnings than Capricor Therapeutics. Capricor Therapeutics is trading at a lower price-to-earnings ratio than Glucose Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Capricor Therapeutics and Glucose Health’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-71.00%	-56.13%
Glucose Health	N/A	N/A	N/A

Volatility and Risk

Capricor Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Glucose Health has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Institutional & Insider Ownership

21.7% of Capricor Therapeutics shares are owned by institutional investors. 10.5% of Capricor Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of current recommendations and price targets for Capricor Therapeutics and Glucose Health, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1	0	9	0	2.80
Glucose Health	0	0	0	0	0.00

Capricor Therapeutics presently has a consensus price target of $40.82, indicating a potential upside of 40.95%. Given Capricor Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Capricor Therapeutics is more favorable than Glucose Health.

Summary

Capricor Therapeutics beats Glucose Health on 7 of the 13 factors compared between the two stocks.

About Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

About Glucose Health

Glucose Health, Inc. engages in the formulation, manufacturing, marketing, and distribution of soluble fiber infused nutritional beverages. It offers soluble fiber infused powdered iced tea, and flavored drink mixes for pre-diabetic and diabetic persons under the GLUCODOWN brand in North America. The company was formerly known as Bio-Solutions Corp. and changed its name to Glucose Health, Inc. in November 2014. Glucose Health, Inc. was incorporated in 2007 and is based in Bentonville, Arkansas.